TY - JOUR
T1 - Immune-based strategies for mood disorders
T2 - facts and challenges
AU - Colpo, Gabriela D.
AU - Leboyer, Marion
AU - Dantzer, Robert
AU - Trivedi, Mahdukar H.
AU - Teixeira, Antonio L.
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Introduction: Inflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions. Expert commentary: Clinical trials with non-steroidal anti-inflammatory drugs, polyunsaturated acids, N-acetylcysteine, anti-cytokines, physical activity and probiotics have provided promising results in terms of antidepressant efficacy in patients with MDD and BD. Regarding stem cells, only studies with animal models have been performed so far with interesting pre-clinical results. Due to the preliminary nature of the results, most of the clinical studies need to be replicated and/or confirmed in larger clinical settings, embracing the highly heterogeneous pathophysiology of mood disorders.
AB - Introduction: Inflammation seems to play a role in the pathophysiology of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). In the last years several studies have shown increased levels of inflammatory and/or immune markers in patients with mood disorders. Accordingly, the immune system has become a target of interest for the development of biomarkers and therapeutics for mood disorders. Areas covered: Here, we review the evidence showing low-grade inflammation in mood disorders and the studies evaluating immune-based strategies for the treatment of these conditions. Expert commentary: Clinical trials with non-steroidal anti-inflammatory drugs, polyunsaturated acids, N-acetylcysteine, anti-cytokines, physical activity and probiotics have provided promising results in terms of antidepressant efficacy in patients with MDD and BD. Regarding stem cells, only studies with animal models have been performed so far with interesting pre-clinical results. Due to the preliminary nature of the results, most of the clinical studies need to be replicated and/or confirmed in larger clinical settings, embracing the highly heterogeneous pathophysiology of mood disorders.
KW - Mood disorders
KW - anti-inflammatory drugs
KW - bipolar disorder
KW - cytokines
KW - immunomodulation
KW - inflammation
KW - major depressive disorder
KW - neuroinflammation
UR - http://www.scopus.com/inward/record.url?scp=85041306875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041306875&partnerID=8YFLogxK
U2 - 10.1080/14737175.2018.1407242
DO - 10.1080/14737175.2018.1407242
M3 - Review article
C2 - 29179585
AN - SCOPUS:85041306875
SN - 1473-7175
VL - 18
SP - 139
EP - 152
JO - Expert review of neurotherapeutics
JF - Expert review of neurotherapeutics
IS - 2
ER -